Compare NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) vs Repligen Corporation Common Stock — how do they compare? NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.57 (market cap $69.79B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 6.3× Repligen Corporation Common Stock's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.34% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| NWG | RGEN | |
|---|---|---|
Market Cap | $69.79B | $11.14B |
Volume | 3,183,982 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $19.42 | $194.57 |
52-Week Low | $13.89 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $142.57B | $11.02B |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NatWest Group (NWG) trades at $17.65, up 2.38% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a low P/E of 8.94 and robust profitability with a net income margin of 36.24%. Recent earnings have consistently beaten expectations, and analyst sentiment is positive, with a 'Moderate Buy' consensus. The company has upgraded its 2026 guidance and accelerated share buybacks, supported by healthy revenue growth and improving deposit margins.
The outlook for NWG is favorable, driven by earnings momentum and supportive analyst coverage, though risks include negative cash flow trends and potential regulatory scrutiny. The stock presents a value opportunity given its attractive valuation and strong return on equity, but investors should monitor execution on profitability targets and macroeconomic impacts on the banking sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
